BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11994759)

  • 21. [ErbB-2 expression and hormone receptor status in areas of transition from in situ to invasive ductal breast carcinoma].
    Peres RM; Derchain SF; Heinrich JK; Serra KP; Pinto GA; Soares FA; Sarian LO
    Rev Bras Ginecol Obstet; 2009 Sep; 31(9):461-7. PubMed ID: 19876578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
    Kunju LP; Ding Y; Kleer CG
    Pathol Int; 2008 Oct; 58(10):620-5. PubMed ID: 18801081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
    Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
    Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there 'progression through grade' in ductal invasive breast cancer?
    Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
    Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
    Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
    Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biofunctional characteristics of in situ and invasive breast carcinoma.
    Bravaccini S; Granato AM; Medri L; Foca F; Falcini F; Zoli W; Ricci M; Lanzanova G; Masalu N; Serra L; Buggi F; Folli S; Silvestrini R; Amadori D
    Cell Oncol (Dordr); 2013 Jul; 36(4):303-10. PubMed ID: 23807750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast.
    Peres RM; Serra KP; Derchain SF; Yoon JH; Pinto GA; Alvarenga M; Soares FA; Heinrich JK; da Cunha IW; Vassallo J; Sarian LO
    Int J Biol Markers; 2009; 24(4):238-44. PubMed ID: 20108215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
    Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
    Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of mammographic appearance and molecular prognostic factors in high-grade breast carcinomas.
    Likaki-Karatza E; Ravazoula P; Androutsopoulos G; Michail G; Batistatou A; Tzorakoleftherakis E; Kalofonos H; Kourounis G
    Eur J Gynaecol Oncol; 2006; 27(1):39-41. PubMed ID: 16550966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and significance of phosphorylated Girdin in breast cancer].
    Xu Y; Fu L; Gu F; Ma YJ
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.